West Pharmaceutical topped Q1 estimates and raised 2025 guidance, citing stronger device demand and improved inventory trends across key markets.
Latest Ratings for WST
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 2021 | Keybanc | Maintains | Overweight | |
| Nov 2020 | Keybanc | Initiates Coverage On | Overweight | |
| Oct 2020 | Stephens & Co. | Initiates Coverage On | Equal-Weight |
